ProKidney Corp. Class A (PROK)
NASDAQ: PROKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PROK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $415.21M
- EPS (TTM)
- -$0.61
- Dividend yield
- None
- 52-week range
- 0.87 – 2.65
- Day range
- 1.02 – 1.08
- Volume / Avg
- 1.90M / 1.44M
- Beta
- —
- Shares outstanding
- 209.63M
52-week range
PROK stock today
Shares of ProKidney (PROK) finished lower on Nov 20 at $1.04, a drop of 1.89% or $0.02 per share, versus the S&P 500's 3.70% decline. At this level, PROK sits near the bottom of its 52-week range of $0.87 to $2.65: 60.8% below the high, set on Dec 5, 2025 and 19.5% above the low. PROK is down 53.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 52.5%.
ProKidney has posted a net loss over the last twelve months (EPS of -$0.61), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ProKidney
Company profileProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Bruce Culleton M.D.
- Headquarters
- Winston-Salem, NC
- Employees
- 231
- IPO year
- 2021
- Website
- prokidney.com
Financial highlights
Full financialsIn fiscal 2025, ProKidney generated $893,000 in revenue, up 1075.0% from fiscal 2024, its 2nd consecutive year of revenue growth. ProKidney reported a net loss of $69.0 million, compared with a loss of $61.2 million a year earlier. Operating margin was -18477.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $893.00K | $76.00K | $0 | $0 | — |
| Growth | +1075.00% | — | — | — | — |
| Net income | $-68.99M | $-61.19M | $-35.47M | $-148.13M | $-55.15M |
| EPS (diluted) | — | — | — | $-0.23 | — |
Analyst forecast
ForecastConsensus (6 analysts)
buy
Avg. price target
$6.50+525.00%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.17 vs $-0.13
- Surprise
- -30.77%
PROK news
All PROK news- ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial AdvancesNasdaqABBV, AMGN, IMVT, PROK
- ProKidney Names Farah Ali, M.D., M.S., Chief Medical OfficerGlobeNewswire
- ProKidney Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewswire
- ProKidney Corp. Reports $141.9 million in Cash and Outlines Phase 3 PROACT 1 MilestonesNasdaq
- ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate UpdateGlobeNewswire
- ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026GlobeNewswire
ProKidney peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs PROK |
| TVGNTevogen Inc. | 5.90 | -6.35% | $405.20M | vs PROK |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs PROK |
| CADLCandel Therapeutics Inc. | 5.04 | -1.75% | $395.37M | vs PROK |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs PROK |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs PROK |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs PROK |
| ALECAlector Inc. | 2.34 | +1.52% | $347.63M | vs PROK |
Indexes, lists and sector
ProKidney stock FAQ
What is ProKidney's stock price today?
PROK last traded at $1.04 as of Nov 20, 4:00 PM EST, down 1.89% on the day. Prices are delayed at least 15 minutes.
Who is ProKidney's CEO?
Dr. Bruce Culleton M.D. is the chief executive officer of ProKidney Corp. Class A, which has about 231 employees.
What is the PROK 52-week high?
The 52-week high for PROK is $2.65 and the 52-week low is $0.87. The stock is currently 60.8% below its high.